Abstract 2052P
Background
Fluorouracil plus leucovorin, oxaliplatin and docetaxel (FLOT) is the standard of care for perioperative chemotherapy in resectable locally advanced gastric cancer (LAGC) in Europe. As a triplet combination, FLOT may be associated with increased toxicity. Therefore, it is crucial to investigate whether patients experience similar toxicities before and after surgery. This study aims to evaluate the toxicity profile of FLOT chemotherapy.
Methods
This observational, longitudinal, retrospective study included patients diagnosed with LAGC and treated with FLOT chemotherapy in a Portuguese medical oncology department between January 2018 and December 2020. Adverse events were classified according to Toxicity Grading CTC-AE version 5.0.
Results
Forty-seven patients with LAGC treated with FLOT chemotherapy were included in this study. The median age at diagnosis was 59.3 years (SD 8.1), and the majority of patients were male (n=29, 61.7%) with an ECOG PS of 0 (n=41, 87.2%). During the first four cycles of FLOT given before surgery, a total of 56 adverse events of any degree were observed, with 8 (17%) patients requiring treatment delay and 4 (8.5%) patients requiring dose reduction. In the 5th to 8th cycles given after surgery, there were 62 adverse events of any degree, with 13 (27.7%) patients requiring treatment delay and dose reduction. Notably, the toxicity profile differed between the pre and post-operative periods. In the first 4 cycles, the most common adverse events were nausea (n=16, 28.6%), emesis (n=9, 16.2%), and diarrhea (n=6, 10.7%), mostly with grade 2 toxicity. In the postoperative period, the main adverse events were neutropenia (n=23, 37.1%), nausea (n=6, 9.7%), and neuropathy (n=6, 9.7%). Grade 3 and 4 neutropenia occurred in 15 and 2 patients, respectively. Forty-two patients completed 8 cycles of FLOT.
Conclusions
The observed differences in toxicity between the pre- and postoperative periods highlight the importance of tailoring the treatment approach based on the patient's individual needs. Efforts to minimize dose reduction and chemotherapy delay should be made to maximize the effectiveness of FLOT therapy. Limitations of this study include the lack of data on long-term toxicity.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2066P - Evaluation of the quality and reliability of ChatGPT and Perplexity's responses about rectal cancer
Presenter: Ozan Yazici
Session: Poster session 06
2067P - Influence of psychiatric disorders on survival in patients with lung cancer: Real-world data
Presenter: Tomi Kovacevic
Session: Poster session 06
2068P - Perspectives and concerns on sexuality among adolescents and young adults treated for testicular germ cell tumour: The PRICELESS-study - A qualitative study
Presenter: Danielle Zweers
Session: Poster session 06
2069P - QoL changes of caregivers during first-line palliative chemotherapy for patients with incurable cancer
Presenter: Nobumichi Takeuchi
Session: Poster session 06
2070P - Assessment of healthy lifestyle habits in breast cancer patients
Presenter: Juan Cristobal Sanchez
Session: Poster session 06
2071P - Identification of top issues and concerns of cancer patients in Korea on social media
Presenter: Joo Han Lim
Session: Poster session 06
2072P - Topical application of mixed agents to reduce oral mucositis during radiotherapy in post operated head and neck cancer
Presenter: Chandra Prakash
Session: Poster session 06
2073P - Medical cannabis: A potential effective treatment for chemotherapy-induced peripheral neuropathy (CIPN)
Presenter: Ravit Geva
Session: Poster session 06
2074P - Oral cannabidiol for prevention of chemotherapy-induced peripheral neuropathy
Presenter: Sebastian Nielsen
Session: Poster session 06